• Maraviroc in Research: Applied Workflows for CCR5 Antagonism

  2026-06-19

  Maraviroc (UK-427857) enables precise, reproducible CCR5 blockade in HIV-1 entry inhibition, HIV tropism studies, and emerging inflammation models. This article distills experimental best practices, troubleshooting strategies, and practical insights—including innovations from recent rheumatoid arthritis research—so you can maximize the value of Maraviroc from APExBIO in your bench workflows.

• Bradykinin as an Endothelium-Dependent Vasodilator in Resear

  2026-06-18

  Bradykinin stands out as the gold-standard endothelium-dependent vasodilator for dissecting vascular permeability, smooth muscle contraction, and inflammation pathways. Discover optimized workflows, troubleshooting strategies, and cross-referenced insights that empower high-impact cardiovascular and pain mechanism research.

• Panobinostat (LBH589): HDAC Inhibition and Apoptosis Inducti

  2026-06-18

  Panobinostat (LBH589) is a potent, broad-spectrum HDAC inhibitor that induces apoptosis in cancer cells via epigenetic modulation and caspase activation. It demonstrates low nanomolar potency and has utility in models of drug-resistant malignancies. APExBIO supplies Panobinostat (A8178) for advanced epigenetic and oncology research.

• PD 0332991 (Palbociclib) HCl: Precision CDK4/6 Inhibition Wo

  2026-06-17

  PD 0332991 (Palbociclib) HCl stands out as a benchmark CDK4/6 inhibitor, enabling robust cell cycle arrest and targeted antiproliferative assays in preclinical cancer models. This guide transforms recent bench discoveries and troubleshooting insights into optimized experimental workflows for maximizing the impact of APExBIO’s PD 0332991 (Palbociclib) HCl.

• TRPV1 and TRPA1 Activation Drives TSLP in Nasal Epithelium

  2026-06-17

  The referenced study clarifies how TRPV1 and TRPA1 channel activation in human nasal epithelial cells stimulates the production of TSLP and other cytokines through a Ca2+/NFAT pathway. These findings provide mechanistic insight into upper airway inflammation and inform experimental approaches for targeting sensory ion channel signaling.

• Gastrin I (human): Unraveling Receptor Biology and Translati

  2026-06-16

  Explore the pivotal role of Gastrin I (human) in decoding gastric acid secretion pathways with unprecedented receptor-level detail. This article uniquely bridges advanced peptide biochemistry with hiPSC-derived intestinal organoid models, delivering actionable insight for gastrointestinal physiology studies.

• EZ Cap™ Human PTEN mRNA (ψUTP): Redefining mRNA Stability an

  2026-06-16

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP) advances in vitro transcribed mRNA research through enhanced stability and immune evasion. This article uniquely connects molecular engineering with translational oncology, highlighting practical assay implications and differentiating itself from existing PTEN mRNA content.

• Oteseconazole (VT-1161): Reliable Antifungal Data for Candid

  2026-06-15

  This evidence-driven article addresses key laboratory challenges in antifungal testing, focusing on Oteseconazole (VT-1161), SKU BA1665. By integrating real-world scenarios, data-backed protocols, and vendor reliability analysis, it empowers researchers and technicians to optimize Candida assays and confidently select Oteseconazole (VT-1161) for robust, reproducible results.

• Strategic Acceleration of MCL1-Targeted Therapeutics in Onco

  2026-06-15

  This thought-leadership article explores the mechanistic and translational significance of targeting MCL1 in overcoming endocrine resistance in breast cancer, leveraging the L1023 Anti-Cancer Compound Library for high-throughput discovery. By integrating recent findings on capsazepine's novel mechanism and mapping strategic workflows for translational research, it offers actionable guidance and a forward-looking vision for oncology drug discovery.

• AZD8055: Technical Guidance for mTOR Pathway Inhibition

  2026-06-14

  AZD8055 is a potent, selective mTOR inhibitor designed for preclinical research dissecting mTORC1 and mTORC2 signaling in cancer and metabolic models. It is not recommended for studies aiming to demonstrate clinical efficacy endpoints, but is highly effective for mechanistic studies requiring dual complex inhibition. This article details actionable workflow guidance and technical boundaries for AZD8055 use.

• AO/PI Double Staining Kit: Precision Cell Viability & Apopto

  2026-06-13

  The AO/PI Double Staining Kit enables rapid, quantitative differentiation of viable, apoptotic, and necrotic cells in complex experimental settings. Its dual-fluorescence design is uniquely suited for high-content organoid models and translational oncology workflows, streamlining both routine and advanced cell fate analysis.

• NF 449: Purinergic Receptor Antagonist Elevates Platelet Res

  2026-06-12

  NF 449, a highly selective purinergic receptor antagonist, streamlines platelet activation studies with unmatched potency at the P2X1 ion channel. Its precision enables advanced antithrombotic agent research, robust workflow reproducibility, and actionable troubleshooting for demanding platelet aggregation assays.

• Aquaporin-1 as a Safe Genetic MRI Reporter Across Cell Types

  2026-06-12

  The referenced study demonstrates that engineering water exchange via aquaporin-1 (Aqp1) enables robust, metal-free MRI contrast in diverse mammalian cells without compromising cell physiology. These findings address safety concerns and pave the way for broader applications of Aqp1 as a noninvasive genetic reporter in molecular and synthetic biology.

• CRISPRi Targeting Fabp4: Adipocyte-Specific Gene Silencing i

  2026-06-11

  This study demonstrates a targeted nonviral CRISPR interference system against Fabp4 in white adipocytes, leading to significant reductions in obesity, inflammation, hepatic steatosis, and insulin resistance in mouse models. The findings highlight a technically robust, tissue-specific gene modulation strategy with potential translational value for metabolic and liver disease research.

• Distinct Pharmacokinetics and Clinical Potential of Fosinopr

  2026-06-11

  The reference study delineates the unique pharmacokinetic profile and clinical potential of fosinopril sodium, a third-generation phosphinic acid ACE inhibitor. Its dual renal-hepatic elimination and robust blood pressure reduction make it a particularly valuable option in hypertension research and patient cohorts with renal impairment.

14778 records 1/986 page Next 12345 下5页 Last page